Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Audit Information

v3.25.1
Audit Information
 12 Months Ended
Dec. 31, 2024
Auditor [Table]  
Auditor Name Kost Forer Gabbay & Kasierer
Auditor Firm ID 1281
Auditor Location Tel-Aviv, Israel
Auditor Opinion [Text Block]

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of CollPlant Biotechnologies Ltd. (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations, shareholders’ equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.